|
|
Background Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects.
Methods In two identical multicenter, double-blind, randomized trials, one conducted in Europe (ClinicalTrials.gov number, NCT00259428
[ClinicalTrials.gov]
) and one conducted in the United States, Canada, Australia, South Africa, and Argentina (termed the non-European trial, NCT00259376
[ClinicalTrials.gov]
), we evaluated the efficacy of dronedarone, with 828 patients receiving 400 mg of the drug twice daily and 409 patients receiving placebo. Rhythm was monitored transtelephonically on days 2, 3, and 5; at 3, 5, 7, and 10 months; during recurrence of arrhythmia; and at nine scheduled visits during a 12-month period. The primary end point was the time to the first recurrence of atrial fibrillation or flutter.
Results In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). The corresponding durations in the non-European trial were 59 and 158 days (P=0.002). At the recurrence of arrhythmia in the European trial, the mean (±SD) ventricular rate was 117.5±29.1 beats per minute in the placebo group and 102.3±24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in the non-European trial were 116.6±31.9 and 104.6±27.1 beats per minute (P<0.001). Rates of pulmonary toxic effects and of thyroid and liver dysfunction were not significantly increased in the dronedarone group.
Conclusions Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.
Source Information
From the Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA — both in Los Angeles (B.N.S.); the University of Hamilton, Hamilton, ON, Canada (S.J.C.); the University of Maastricht, Maastricht, the Netherlands (H.J.G.M.C.); the University of Montreal, Montreal (D. Roy); Lankenau Hospital and Institute of Medical Research, Philadelphia (P.R.K.); Ospedale Clinical, Taverna, Italy (A.C.); Sanofi-Aventis, Paris (D. Radzik); Hôpital Central, Nancy, France (E.M.A.); and Goethe University, Frankfurt, Germany (S.H.H.).
Address reprint requests to Dr. Singh at Veterans Affairs Greater Los Angeles Healthcare System, Cardiology Division, 11301 Wilshire Blvd., Los Angeles, CA 90073, or at bsingh{at}ucla.edu.
Related Letters:
Dronedarone in Atrial Fibrillation
Arlet J.-B., Chouchana L., Capron L., Fink A. H. Jr., Singh B. N., Hohnloser S. H., Ezekowitz M. D.
Extract |
Full Text |
PDF
N Engl J Med 2007;
357:2403-2405, Dec 6, 2007.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
Previous
